SUBSCRIBE
SUBSCRIBE
News   Drug Development

AustCancer Commences Phase II Clinical Study Of RP101 For Metastatic Pancreatic Cancer

October 19, 2005 | 
1 min read
SYDNEY, Australia--(BUSINESS WIRE)--Dec. 14, 2004--Australian Cancer Technology ("AustCancer") (ASX:ACU) today said it has initiated a Phase II clinical study of RP101 for the treatment of metastatic pancreatic cancer.
Clinical research Phase II
MORE ON THIS TOPIC
Novo Nordisk's logo on the facade of its building in Germany
Obesity
Novo’s Amylin Injectable Cagrilintide Hits 11.8% Weight Reduction in Phase III Trial
September 16, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
man pulling each of the opposite ends of a rope in black and white, on a blue background with some blank space on top
Obesity
Novo, Lilly Jostle For Market Lead in Obesity With New Regulatory Efforts
September 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Focal seizure. Vector illustration of human brain and electroencephalograhy or EEG originating from temporal lobe.
Gene therapy
Capsida Reports Patient Death in Gene Therapy Trial
September 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Goal concept. Human hand in dotted pop art style pointing on the target for red paper plane. Vector illustration
Duchenne muscular dystrophy
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA
September 11, 2025
 · 
2 min read
 · 
Tristan Manalac